topotecan has been researched along with carboplatin in 198 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (3.03) | 18.2507 |
| 2000's | 102 (51.52) | 29.6817 |
| 2010's | 77 (38.89) | 24.3611 |
| 2020's | 13 (6.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ozols, RF | 1 |
| Kaufmann, SH; Rowinsky, EK | 1 |
| Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Morrissey, LH | 1 |
| Chakravarthy, A; Choy, H; Johnson, D | 1 |
| Blessing, JA; DeGeest, K; Herzog, TJ; Look, KY; Markman, M; Morgan, M; Rose, PG | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Cacciari, N; Martoni, A; Zamagni, C | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ | 1 |
| Bolis, G; Mangili, G; Parazzini, F; Scarfone, G; Tateo, S; Villa, A | 1 |
| Adams, AL; Boente, M; Bookman, MA; Ciccotto, S; Gallo, JM; Millenson, MM; Ozols, RF; Padavic-Shallers, K; Rogatko, A; Rogers, B; Rosenblum, N; Schilder, RJ; Weiner, LM | 1 |
| Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D | 1 |
| Bolis, G; Parazzini, F; Scarfone, G; Villa, A | 1 |
| Cantrell, CL; Dunleavy, TL; Dunphy, FR; Harrison, BR; Petruska, PJ; Pincus, SM; Richart, JM; Visconti, JL | 1 |
| Bowman, A; Ross, G; Rye, T; Smyth, JF; Wheatley, A | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Bookman, MA | 4 |
| Fields, SZ; Hearn, S; Martoni, A; Pujol, JL; Ross, G; Tumolo, S; von Pawel, J | 1 |
| Boulad, F; Calleja, E; Cheung, NK; Dunkel, IJ; Kramer, K; Kushner, BH | 1 |
| Bolis, G; Guarnerio, P; Parazzini, F; Polverino, GP; Rosa, C; Scarfone, G; Sciatta, C | 1 |
| du Bois, A | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Athale, UH; Gajjar, A; Heideman, RL; Kuttesch, JF; Meyer, W; Moghrabi, A; Pratt, C; Stewart, C | 1 |
| Thigpen, T | 1 |
| Battaglia, A; Bonanno, G; Distefano, M; Fattorossi, A; Ferlini, C; Mancuso, S; Pierelli, L; Scambia, G | 1 |
| Doherty, MG; Gordon, AN; Hancock, KC; Matthews, CM; Messing, M; Stringer, CA; Teneriello, M | 1 |
| Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C | 1 |
| Boddy, AV; Calvert, AH; Calvert, PM; Fishwick, K; Griffin, MJ; Ross, GA; Schätzlein, A; Simpson, AB; Sludden, JA; Twelves, CJ; Wheatley, A; Wilson, P | 1 |
| Burris, HA; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Morrissey, LH; Prasthofer, EF; Scullin, DC | 1 |
| Negoro, S | 1 |
| Boiocchi, M; Raffin, L; Sartor, F; Sorio, R; Toffoli, G; Veronesi, A | 1 |
| Dropcho, S; Fife, K; Hanna, N; Seitz, DE; Sweeney, C | 1 |
| Gabryś, M; Gerber, J; Goluda, M; Jedryka, M | 1 |
| Bookman, M; Copeland, LJ; Trimble, E | 1 |
| Herzog, TJ; Holloway, RW; Stuart, GC | 1 |
| Greco, FA | 1 |
| Dowlati, A; Levitan, N | 1 |
| Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV | 1 |
| Agarwal, R; Foster, T; Guppy, AE; Nelstrop, AE; Rustin, GJ; Seckl, MJ | 1 |
| Ali, K; Fung, MF; Hopkins, L; Le, T; Leis, A; Pahwa, P; Reeder, B; Wright, K | 1 |
| Pfisterer, J | 1 |
| Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 1 |
| Bogart, JA; Green, MR; Herndon, JE; Lee, ME; Lyss, AP; Miller, AA; Turrisi, AT; Watson, D | 1 |
| Castellano, A; Cozza, R; De Laurentis, C; De Sio, L; Deb, G; Dominici, C; Donfrancesco, A; Fidani, P; Ilari, I; Inserra, A; Jenkner, A; Milano, GM | 1 |
| Biamonte, R; Cartenì, G; Danese, S; De Laurentiis, M; De Matteis, A; De Placido, S; Di Vagno, G; Febbraro, A; Gallo, C; Gasparini, G; Greggi, S; Lauria, R; Lombardi, AV; Manzione, L; Marinaccio, M; Naglieri, E; Perrone, F; Pignata, S; Scambia, G; Valerio, MR | 1 |
| Haller, G; Horak, P; Krainer, M; Pils, D; Pribill, I; Rössler, M; Tomek, S; Zielinski, CC | 1 |
| Christensen, IJ; Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C | 1 |
| Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ | 1 |
| Herzog, TJ | 1 |
| Bookman, MA; Gallo, JM; Guo, P; Li, S; Ma, J; Orlansky, A; Pulfer, S; Vicini, P; Zhou, F | 1 |
| Casas, F; Jeremic, B | 1 |
| Beijnen, JH; Bos, AM; De Vos, FY; de Vries, EG; Gietema, JA; Mourits, MJ; Rosing, H; van der Zee, AG; Willemse, PH | 1 |
| Altundag, K; Altundag, O; Gunduz, M; Morandi, P | 1 |
| Burges, A; du Bois, A; Gropp, M; Harter, P; Huober, J; Pfisterer, J; Schade-Brittinger, C; Schmalfeldt, B; Staehle, A; Wollschlaeger, K | 1 |
| Beeler, JF; Haba, P; Rose, PG; Smrekar, M; Visser, C | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Gojo, I; Greer, J; Karp, JE; Kaufmann, SH; Kottke, TJ; Letendre, L; Litzow, MR; Loegering, DA; Reid, JM; Safgren, S; Sloan, JA; Svingen, PA | 1 |
| Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG | 1 |
| Donahue, A; Faucette, S; Gillenwater, HH; Kirstein, MN; Lindley, C; McCune, JS; Moore, D; Shord, S; Socinski, MA; Stewart, CF; Zamboni, WC | 1 |
| Dyer, MA; Egorin, M; Gray, JK; Laurie, NA; Leggas, M; Relling, M; Stewart, C; Zhang, J | 1 |
| Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS | 1 |
| Belinson, JL; Michener, CM | 1 |
| Biamonte, R; Cartenì, G; Colucci, G; Danese, S; de Matteis, A; De Placido, S; Di Maio, M; Di Vagno, G; Febbraro, A; Gasparini, G; Lombardi, AV; Manzione, L; Marinaccio, M; Massidda, B; Nardi, M; Perrone, F; Pignata, S; Pisano, C; Scambia, G; Valerio, MR | 1 |
| Cheung, NK; Danis, K; Kernan, NA; Kramer, K; Kushner, BH; Modak, S; Reich, LM | 1 |
| Cheung, IY; Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Bookman, MA; Fracasso, PM; McMeekin, DS | 1 |
| Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A | 1 |
| Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM | 1 |
| McGuire, WP | 1 |
| Blohmer, JU; Bourgeois, H; Costa, S; du Bois, A; Geay, JF; Hardy-Bessard, AC; Jackisch, C; Kimmig, R; Kuhn, W; Lortholary, A; Lück, HJ; Meden, H; Meier, W; Möbus, V; Nitz, U; Olbricht, S; Pfisterer, J; Pujade-Lauraine, E; Quaas, J; Reuss, A; Richter, B; Schröder, W; Stähle, A; Wagner, U; Weber, B | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Al Omari, A; Case, D; Miller, AA; Murry, DJ | 1 |
| Collado, MV; García Villanueva, A; Pérez de Oteyza, J; Rojo, R; Ruiz-Tovar, J | 1 |
| Grønlund, B | 1 |
| Canales Ugarte, S; Cassinello Espinosa, J | 1 |
| Anderson, E; Andrews, C; Bjurstrom, T; Blackwell, S; Campagna, L; Crawford, J; Garst, J; Herndon, JE; Maravich-May, D; Padilla, K; Shafman, T | 1 |
| Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A | 1 |
| Atkins, JN; Bearden, JD; Crowley, JJ; Dakhil, SR; Dunphy, FR; Gandara, DR; Giguere, JK; Hesketh, PJ; Kelly, K; McCoy, J; Weiss, GR | 1 |
| Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E | 1 |
| Ajlouni, M; Chapman, R; Kim, JH; Lu, M; Movsas, B; Patel, SH | 1 |
| Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W | 1 |
| Belau, A; Bogenrieder, T; Camara, O; Coumbos, A; Klare, P; Koensgen, D; Lichtenegger, W; Mustea, A; Oskay-Oezcelik, G; Sehouli, J; Sommer, H; Steck, T; Stengel, D | 1 |
| Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
| Bamias, A; Giannopoulos, A; Gourgoulis, G; Mountzios, G; Papaiakovou, EE; Rodolakis, A; Vlahos, G; Voulgaris, Z | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Cui, BX; Jiang, J; Kong, BH; Meng, LH; Su, SL; Wang, B; Wang, LJ; Yang, XS; Zhang, YZ | 1 |
| An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT | 1 |
| Amini, E; Cairo, MS; Fuller, GN; Ketonen, L; Kobrinsky, N; Lee, A; Mahajan, A; Roffidal, T; Wells, RJ; Wolff, JE | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Papadimitriou, CA; Pectasides, D | 1 |
| Castleberry, R; Kletzel, M; Kretschmar, C; London, WB; Marcus, R; Murray, K; Zage, PE; Zhang, Y | 1 |
| Ross, HJ; Seung, SK | 1 |
| Budning, A; Chan, HS; Dai, S; Dimaras, H; Doyle, J; Drake, J; Gallie, BL; Halliday, W; Héon, E | 1 |
| Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J | 1 |
| Karp, J | 1 |
| Hoskins, PJ | 1 |
| Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL | 1 |
| Kakavelas, P; Kontakiotis, T; Lithoxopoulou, H; Mylonaki, E; Rapti, E; Tsiouda, T; Zarogoulidis, K; Zarogoulidis, P; Zarogoulidou, V | 1 |
| Fukuoka, M; Kashii, T; Kobayashi, M; Kurata, T; Nakagawa, K; Satoh, T; Seki, N; Takeda, K; Tsuboi, M | 1 |
| Gil, M; Horwacik, I; Kowalczyk, A; Kozbor, D; Odrowaz, Z; Rokita, H | 1 |
| Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R | 1 |
| Bae, DS; Choi, CH; Kang, H; Kim, BG; Kim, TJ; Lee, JW; Lee, YY | 1 |
| Beijnen, JH; Boss, DS; Pluim, D; Rosing, H; Schellens, JH; Siegel-Lakhai, WS; Ten Bokkel Huinink, WW; van Egmond-Schoemaker, NE | 1 |
| Ames, MM; Ansell, SM; Barrette, BA; Dispenzieri, A; Elliott, MA; Frost, MH; Gastineau, DA; Gertz, MA; Hartmann, LC; Inwards, DJ; Kaufmann, SH; Keeney, GL; Lacy, MQ; Lingle, WL; Litzow, MR; Long, HJ; Micallef, IN; Peethambaram, PP; Porrata, LF; Reid, JM; Safgren, SL; Suman, VJ | 1 |
| Adjei, AA; Bryce, AH; Hillman, SL; Jett, JR; Kugler, JW; Mattar, B; Perez, EA; Rowland, K; Soori, G; Wender, DB | 1 |
| Boulad, F; Dunkel, IJ; Gilheeney, SW; Khakoo, Y; Souweidane, M; Wolden, S | 1 |
| Al-Kadhimi, Z; Chow, W; Doroshow, JH; Frankel, P; Leong, L; Lim, D; Mamelak, A; Margolin, K; Morgan, RJ; Shibata, S; Somlo, G; Synold, T; Twardowski, P; Yen, Y | 1 |
| Abramson, DH; Brodie, SE; Dunkel, IJ; Gobin, YP; Marr, B | 1 |
| Alvarez, RD; Bryant, CS; Deppe, G; Kumar, S; Morris, RT; Munkarah, AR; Shah, JP; Spannuth, W | 1 |
| Burris, HA; Clark, BL; Gandhi, JG; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Peyton, JD; Spigel, DR; Vazquez, ER; West-Osterfield, K | 1 |
| Aimone, PD; Bolis, G; Danese, S; Lo Russo, D; Mangili, G; Raspagliesi, F; Scambia, G; Scarfone, G; Scollo, P; Villa, A | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| Carcaboso, AM; Dyer, MA; Egorin, M; Federico, S; Nemeth, KM; Schaiquevich, P; Shen, Y; Stewart, C; Zhang, J | 1 |
| Athanasopoulos, A; Daladimos, T; Karabelis, A; Kosmas, C; Mylonakis, N; Theotikos, E; Tsakonas, G | 2 |
| Brotto, L; Casado, A; Cervantes, A; Chen, D; D'Hondt, V; Eisenhauer, EA; Elit, L; Germa, JR; Ghatage, P; Grimshaw, R; Hoskins, P; Katsaros, D; Mendiola, C; Ojeda, B; Oza, A; Poveda, A; Provencher, D; Roy, M; Stuart, G; Sugimoto, A; Tu, D; Vergote, I; Zola, P | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Hartney, J; Lane, S; Legenne, P; Monk, BJ; Provencher, D; Rose, PG | 1 |
| Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; Ravà, L | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Amin, MS; Eisenhauer, EA; Hoskins, PJ; Islam, S; O'Brien, AM; Pelletier, LB; Squire, JA; Tu, D; Weberpals, JI | 1 |
| Babyn, P; Chan, HS; Dimaras, H; Doyle, J; Gallie, BL; Halliday, W; Héon, E; Paton, KE; Strahlendorf, C | 1 |
| Cassier, P; Chapet, O; Chekrine, T; De Bari, B; Kulisa, M; Mornex, F | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Alexandre, J; Dauba, J; Durando, X; Gladieff, L; Largillier, R; Lortholary, A; Paraiso, D; Pujade-Lauraine, E; Slama, B; Weber, B | 1 |
| Ambrosone, CB; Armstrong, DK; Bookman, MA; Darcy, KM; Davis, W; DeLoia, JA; Gallion, H; Krivak, TC; Moysich, K; Tian, C; Zhao, H | 1 |
| Abramson, DH; Brodie, SE; Dunkel, IJ; Gobin, YP; Hung, C; Marr, BP | 1 |
| Jafari, M; Kislukhin, G; Long, AD; Murphy, ML | 1 |
| Fabbro, M; Floquet, A; Freyer, G; Gladieff, L; Hardy-Bessard, AC; Joly, F; Kaminski, MC; Kurtz, JE; Pujade-Lauraine, E; Raban, N; Ray-Coquard, I | 1 |
| Jia, L; Kong, B; Li, D; Xu, Y; Zhang, H; Zhou, XC | 1 |
| Abramson, DH; Brodie, SE; Dunkel, IJ; Gobin, YP; Marr, BP | 1 |
| Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B | 1 |
| Beilken, A; Bochennek, K; Claviez, A; Dantonello, T; Dirksen, U; Klingebiel, T; Koscielniak, E; Sauerbrey, A | 1 |
| Abramson, DH; Brodie, SE; Dunkel, IJ; Francis, JH; Gobin, YP; Jonna, G; Marr, BP | 1 |
| Curtin, J; Downey, A; Edwards, S; Kwa, M; Muggia, F; Reich, E; Wallach, R | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Abramson, DH; Brodie, SE; Dunkel, IJ; Francis, JH; Gobin, YP; Marr, BP; Riedel, ER | 1 |
| Arepalli, SA; Caywood, EH; Jabbour, P; Lally, SE; Manjandavida, FP; Pieretti, G; Shields, CL; Shields, JA | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L | 1 |
| Carrasco, R; Cruz, O; de Torres, C; Guillen, A; Lavarino, C; Mañé, S; Mora, J; Parareda, A; Rios, J; Salvador, H; Suñol, M; Vancells, M | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Bansal, N; Koundanya, V; Ramamurthy, S; Ravikumar, R; Rishi, P; Saravanan, M; Sharma, T | 1 |
| Brotto, L; Brundage, M; Casado, HA; Cervantes, A; Eisenhauer, E; Hoskins, P; Poveda, A; Tu, D; Vergote, I | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Fujimoto, D; Ito, J; Katakami, N; Kato, R; Kogo, M; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Sato, Y; Shimizu, R; Teraoka, S; Tomii, K | 1 |
| Abruzzo, TA; Augsburger, JJ; Corrêa, ZM; Geller, JI; Lane, A; Michaels, ST | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Aisenbrey, S; Hagemann, U; Januschowski, K; Schnichels, S; Schrader, M; Süsskind, D | 1 |
| Abramson, DH; Brodie, SE; Dunkel, IJ; Fabius, AW; Francis, JH; Gobin, YP; Marr, BP; Mondesire-Crump, I | 1 |
| Hasanreisoglu, M; Iyer, PG; Jabbour, P; Lally, SE; Say, EA; Shields, CL; Shields, JA | 1 |
| Abramson, DH; Chantada, GL; Fabius, AW; Francis, JH; Schaiquevich, P | 1 |
| Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A | 1 |
| Billups, CA; Brennan, RC; Hoehn, ME; Mao, S; Qaddoumi, I; Rodriguez-Galindo, C; Stewart, CF; Wilson, MW; Wu, J | 1 |
| Beck-Popovic, M; Fabian, ID; Gaillard, MC; Munier, FL; Puccinelli, F | 1 |
| Abramson, DH; Brodie, SE; Francis, JH; Gobin, YP; Iyer, S | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Choi, YS; Jo, DY; Kim, JM; Ko, YB; Lee, HJ; Ryu, H; Song, IC; Yun, HJ | 1 |
| Ceciliano, A; Chantada, GL; Fandiño, A; Funes, S; Lagomarsino, E; Manzitti, J; Neira, P; Peralta, L; Sampor, C; Schaiquevich, P; Sgroi, M; Villasante, F | 1 |
| Abramson, DH; Brodie, SE; Dunkel, IJ; Francis, JH; Gobin, YP; Levin, A; Mauguen, A; Mondesire-Crump, I; Rowlands, MA | 1 |
| Honavar, SG; Mulay, K; Rao, R; Reddy, VAP | 1 |
| Bloomfield, A; Dircksen, C; Dorton, R; Kleindl, P; Leamon, CP; Nelson, M; Reddy, JA; Santhapuram, H; Vetzel, M; Vlahov, IR | 1 |
| Ancona-Lezama, D; Dalvin, LA; Jabbour, P; Lucio-Alvarez, JA; Masoomian, B; Shields, CL | 1 |
| Bosaleh, A; Chantada, G; Deu, A; Fandiño, A; Requejo, F; Rodriguez, A; Sampor, C; Schaiquevich, P; Sgroi, M; Zugbi, S | 1 |
| Ancona-Lezama, D; Dalvin, LA; Jabbour, P; Lucio-Alvarez, JA; Shields, CL | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Kim, JC; Kim, JH; Kim, YM; Yoon, YS | 1 |
| Abramson, DH; Brodie, S; Francis, JH; Gobin, YP; Levin, AM; McFadden, M | 1 |
| du Bois, A; Harter, P; Hedderich, J; Heilmann, T; Hempel, AM; Hilpert, F; Pfisterer, J; Pujade-Lauraine, E; Saß, S | 1 |
| Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S | 1 |
| Asher, R; Friedlander, M; Gebski, V; Gonzalez-Martin, A; Hardy-Bessard, AC; Hilpert, F; Kaminsky, MC; Kurzeder, C; Largillier, R; Lee, CK; Lesoin, A; Lortholary, A; Poveda, A; Pujade-Lauraine, E | 1 |
| Cheon, JE; Choi, JY; Choi, YH; Hong, CR; Hong, KT; Kang, HJ; Kim, IH; Kim, SK; Lee, YJ; Park, JD; Park, KD; Park, SH; Phi, JH; Shin, HY; Wang, KC | 1 |
| Jabbour, P; Leahey, AM; Selzer, EB; Shields, CL; Welch, RJ | 1 |
| Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
| Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS | 1 |
| Daniels, AB; Friedman, DL; Froehler, MT; Zheng, Y | 1 |
| Arrieta, O; Lara-Mejía, L; Zatarain-Barrón, ZL | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Basse, C; El Kaddissi, A | 1 |
| Chen, H; Horita, N; Takeshi, K | 1 |
| Baize, N; Chouaid, C; Monnet, I | 1 |
| Acosta, G; Fiani, B; Haynes, M; Nikolaidis, D; Rose, A; Runnels, J; Wong, A | 1 |
| Abramson, DH; Francis, JH; Gobin, YP | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Abramson, DH; Antal, Z; Dunkel, IJ; Francis, JH; Friedman, DN; Gobin, YP; Marathe, PH | 1 |
| Ebinger, M; Fuchs, J; Heinz, AT; Klingebiel, T; Koscielniak, E; Kratz, CP; Ljungman, G; Münter, MW; Pajtler, KW; Rößler, J; Schönstein, A; Seitz, G; Sparber-Sauer, M; Stegmaier, S; Timmermann, B; Vokuhl, C; von Kalle, T | 1 |
25 review(s) available for topotecan and carboplatin
| Article | Year |
|---|---|
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
Topotecan in combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Paclitaxel; Suramin; Topoisomerase I Inhibitors; Topotecan | 1997 |
The role of radiation, with or without chemotherapy, in the management of NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine | 1999 |
Pharmacokinetically guided administration of chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Carboplatin; Cisplatin; Etoposide; Fluorouracil; Humans; Topotecan | 2000 |
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Topotecan | 2001 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2001 |
Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Analysis; Topotecan; Treatment Outcome | 2001 |
Treatment of advanced ovarian cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2002 |
[Nogitecan hydrochloride].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan | 2002 |
Workshop: options for therapy in ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan | 2003 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Topotecan | 2006 |
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
Central neurocytoma responsive to topotecan, ifosfamide, carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Disease-Free Survival; Humans; Ifosfamide; Magnetic Resonance Imaging; Male; Neurocytoma; Remission Induction; Topotecan | 2008 |
Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Paclitaxel; Radiography; Salvage Therapy; Topotecan; Transplantation, Autologous; Wilms Tumor; Young Adult | 2010 |
[Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature].
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma in Situ; Carcinoma, Neuroendocrine; Carcinoma, Transitional Cell; Combined Modality Therapy; Emergencies; Etoposide; Humans; Lymphatic Irradiation; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Prognosis; Prostatic Hyperplasia; Topoisomerase I Inhibitors; Topotecan; Urinary Bladder Neoplasms | 2011 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Topotecan | 2012 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
OCULAR PHARMACOLOGY OF CHEMOTHERAPY FOR RETINOBLASTOMA.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Infusions, Intra-Arterial; Injections, Intraocular; Melphalan; Retinal Neoplasms; Retinoblastoma; Topotecan | 2017 |
The role for intra-arterial chemotherapy for refractory retinoblastoma: a systematic review.
Topics: Antineoplastic Agents; Bronchial Spasm; Carboplatin; Drug Resistance, Neoplasm; Edema; Eyelashes; Febrile Neutropenia; Humans; Infusions, Intra-Arterial; Melphalan; Methotrexate; Nausea; Retinal Neoplasms; Retinoblastoma; Salvage Therapy; Topotecan; Vitreous Hemorrhage; Vomiting | 2021 |
74 trial(s) available for topotecan and carboplatin
| Article | Year |
|---|---|
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome | 1998 |
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome | 1999 |
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan | 1999 |
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan | 2000 |
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2000 |
Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm, Residual; Paclitaxel; Topotecan | 2001 |
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Topotecan | 2001 |
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2001 |
Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan | 2001 |
Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Topotecan; Treatment Outcome | 2001 |
Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Survival Rate; Topotecan | 2001 |
Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neuroblastoma; Radiotherapy, Adjuvant; Remission Induction; Thiotepa; Topotecan; Treatment Outcome | 2001 |
A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan | 2001 |
Phase I study of combination topotecan and carboplatin in pediatric solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Likelihood Functions; Male; Maximum Tolerated Dose; Neoplasms; Salvage Therapy; Topotecan | 2002 |
Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan | 2002 |
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Survival Rate; Topotecan | 2002 |
Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Topotecan; Treatment Outcome | 2002 |
Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2003 |
[Own experiences in salvage chemotherapy of ovarian cancer--a preliminary report].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Time Factors; Topotecan; Treatment Outcome | 2002 |
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan | 2003 |
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2003 |
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Small Cell Lung Carcinoma; Survival Analysis; Topotecan | 2004 |
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Palliative Care; Temozolomide; Topotecan; Treatment Outcome | 2004 |
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome | 2004 |
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2004 |
Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan | 2004 |
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Topotecan; Vidarabine | 2004 |
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Outcome | 2005 |
A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2005 |
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Cell Cycle Proteins; Combined Modality Therapy; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Immunoblotting; Infusions, Intravenous; Leukemia; Male; Middle Aged; Neoplasm Recurrence, Local; Proliferating Cell Nuclear Antigen; Topotecan; Treatment Outcome | 2005 |
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival; Topotecan; Treatment Outcome | 2005 |
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan | 2005 |
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Severity of Illness Index; Time Factors; Topotecan | 2006 |
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Thiotepa; Topotecan; Treatment Failure | 2006 |
Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Administration Schedule; Epithelial Cells; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Topotecan | 2006 |
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2006 |
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; France; Germany; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Topotecan; Treatment Failure | 2006 |
Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Probability; Prognosis; Risk Factors; Survival Analysis; Topotecan | 2006 |
A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Topotecan | 2008 |
[Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan; Treatment Outcome | 2007 |
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan | 2008 |
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Topotecan | 2008 |
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan | 2009 |
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan | 2009 |
A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Young Adult | 2009 |
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism | 2009 |
Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate; Topotecan | 2009 |
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 2009 |
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2010 |
Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.
Topics: Administration, Oral; Adult; Aged; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors; Topotecan; Treatment Outcome | 2010 |
Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Neoplasm Recurrence, Local; Prognosis; Thiotepa; Topotecan; Young Adult | 2010 |
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Spinal Cord Neoplasms; Tamoxifen; Topotecan; Young Adult | 2010 |
Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Infant; Infusions, Intra-Arterial; Male; Melphalan; Ophthalmic Artery; Prospective Studies; Retinal Neoplasms; Retinoblastoma; Topotecan; Treatment Outcome; Visual Acuity | 2010 |
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Topotecan | 2010 |
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Outcome; Young Adult | 2010 |
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2010 |
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan | 2011 |
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan | 2012 |
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Topotecan; Young Adult | 2012 |
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Recurrence; Topotecan; Uterine Cervical Neoplasms | 2012 |
Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Soft Tissue Neoplasms; Survival Rate; Topotecan; Treatment Outcome | 2013 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Image; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life; Surveys and Questionnaires; Topotecan | 2016 |
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan | 2016 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nomograms; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan | 2019 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
99 other study(ies) available for topotecan and carboplatin
| Article | Year |
|---|---|
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Survival Rate; Taxoids; Thiophenes; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
A new method to evaluate in vitro myelotoxicity of antitumour agents in the first steps of drug development.
Topics: Antigens, CD34; Antineoplastic Agents; Carboplatin; Cell Differentiation; Cell Division; Cell Survival; Cells, Cultured; Doxorubicin; Erythropoiesis; Flow Cytometry; Glycophorins; Granulocytes; Humans; Leukapheresis; Myeloid Progenitor Cells; Reproducibility of Results; Thrombopoietin; Time Factors; Topotecan | 2001 |
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
Topics: Age Factors; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Topotecan | 2002 |
Carboplatin and topotecan combination and myelosuppression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Child; Humans; Topotecan | 2002 |
Topotecan as first-line therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan | 2003 |
Combination chemotherapy with topotecan for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2003 |
Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Quality of Life; Topotecan | 2004 |
Recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carboplatin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Caspases; Cell Line, Tumor; Chondrocytes; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Osteoprotegerin; Ovarian Neoplasms; Paclitaxel; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Tumor Necrosis Factor-alpha | 2004 |
Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prognosis; Retrospective Studies; Topotecan | 2004 |
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Computer Simulation; Cyclohexanes; Dacarbazine; Female; Humans; Male; Models, Biological; O-(Chloroacetylcarbamoyl)fumagillol; Ovarian Neoplasms; Predictive Value of Tests; Rats; Rats, Inbred F344; Rats, Nude; Sesquiterpenes; Temozolomide; Topotecan; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2004 |
In regard to Bogart et al.: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage non-small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 (Int J Radiat Oncol Biol Phys 2004;59:460-468).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage; Recurrence; Topotecan | 2004 |
CA125 Nadir values as a prognostic factor in epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prognosis; Topotecan | 2005 |
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Patient Participation; Patient Selection; Prospective Studies; Retrospective Studies; Topotecan | 2005 |
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan | 2006 |
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Etoposide; Eye; Humans; Mice; Mice, Knockout; Rats; Retinal Neoplasms; Retinoblastoma; Time Factors; Topotecan; Vincristine; Xenograft Model Antitumor Assays | 2005 |
Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Secondary Prevention; Topotecan | 2005 |
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Topics: Adolescent; Adult; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Infant; Male; Melphalan; Mice; Neuroblastoma; Retrospective Studies; Thiotepa; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2007 |
Is it time for some new approaches for treating advanced ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Failure | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Papillary serous carcinoma of peritoneum: presentation of 2 cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Postoperative Care; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Topotecan; Treatment Outcome | 2006 |
Cerebral and parotid metachronous metastases from an ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Anticonvulsants; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Parotid Neoplasms; Supratentorial Neoplasms; Topotecan | 2006 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine | 2007 |
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |
Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Topotecan | 2008 |
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome | 2007 |
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine | 2008 |
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2008 |
Trilateral retinoblastoma with pituitary-hypothalamic dysfunction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Etoposide; Fatal Outcome; Female; Gestational Age; Humans; Hypothalamic Diseases; Infant; Infusions, Parenteral; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pituitary Neoplasms; Retinal Neoplasms; Retinoblastoma; Retinoblastoma Protein; Tomography, X-Ray Computed; Topotecan; Vincristine | 2008 |
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2009 |
Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Tolerance; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2009 |
The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carboplatin; Cell Adhesion; Cell Line, Tumor; Doxorubicin; Drug Synergism; Flow Cytometry; Gangliosides; Humans; Immunotherapy; Microscopy, Fluorescence; Neuroblastoma; Topotecan | 2009 |
Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2011 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Conjunctiva; Disease Models, Animal; Humans; Mice; Mice, Inbred C57BL; Rats; Retinal Neoplasms; Retinoblastoma; Topotecan; Visual Acuity; Xenograft Model Antitumor Assays | 2011 |
Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Melphalan; Nephrectomy; Topotecan; Wilms Tumor; Young Adult | 2011 |
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome | 2011 |
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Mesna; Neuroblastoma; Pilot Projects; Risk Factors; Thoracic Neoplasms; Topotecan; Treatment Outcome | 2011 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan | 2011 |
Multifaceted chemotherapy for trilateral retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cyclosporine; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Pineal Gland; Retinal Neoplasms; Retinoblastoma; Tomography, X-Ray Computed; Topotecan; Vincristine | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Flow Velocity; Carboplatin; Child; Child, Preschool; Female; Fluorescein Angiography; Humans; Infant; Infusions, Intra-Arterial; Male; Melphalan; Ophthalmic Artery; Orbit; Regional Blood Flow; Retinal Neoplasms; Retinoblastoma; Topotecan; Young Adult | 2012 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Fertility; Floxuridine; Gemcitabine; High-Throughput Screening Assays; Humans; Methotrexate; Mitomycin; Models, Animal; Neoplasms; Topotecan | 2012 |
Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Infusions, Intra-Arterial; Male; Melphalan; Middle Aged; Pilot Projects; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Young Adult | 2012 |
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2013 |
Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Combined Modality Therapy; Electroretinography; Eye Neoplasms; Female; Humans; Infant; Male; Ophthalmic Artery; Retinoblastoma; Topotecan | 2013 |
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystadenocarcinoma, Serous; Etoposide; Female; Floxuridine; Follow-Up Studies; Heterozygote; Humans; Injections, Intraperitoneal; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Survival Rate; Topotecan | 2014 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review.
Topics: Carboplatin; Electroretinography; Humans; Melphalan; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Topotecan; Treatment Outcome | 2014 |
Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Infant; Infusions, Intra-Arterial; International Classification of Diseases; Male; Melphalan; Microscopy, Acoustic; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan; Treatment Outcome; Young Adult | 2014 |
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude of Health Personnel; Carboplatin; Child; Child, Preschool; Curriculum; Databases, Factual; Education, Medical; Enzyme Inhibitors; Etoposide; Europe; Female; General Surgery; Germany; Hospitals, University; Humans; Ifosfamide; Lung Neoplasms; Male; Medical History Taking; Mesothelioma; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Neurons; Muscular Atrophy; Neoplasms; Neuroprotective Agents; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Physical Examination; Quality Improvement; Spinal Cord Injuries; Topotecan; Universities; World Health Organization; Young Adult | 2014 |
Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Cisplatin; Cohort Studies; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Immunotherapy; Induction Chemotherapy; Infant; Isotretinoin; Male; Neoadjuvant Therapy; Neoplasm Staging; Neuroblastoma; Neurosurgical Procedures; Pilot Projects; Prospective Studies; Radiotherapy; Thiotepa; Topotecan; Treatment Outcome; Vincristine | 2015 |
Intra-arterial chemotherapy for retinoblastoma: First Indian report.
Topics: Antineoplastic Agents; Carboplatin; Child, Preschool; Dose-Response Relationship, Drug; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Incidence; India; Infant; Injections, Intra-Arterial; Male; Melphalan; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2015 |
Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intra-Arterial; Male; Melphalan; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan | 2016 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
Toxic effects of melphalan, topotecan and carboplatin on retinal pigment epithelial cells.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Caspase 3; Caspase 7; Cell Count; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Melphalan; Microscopy, Phase-Contrast; Retinal Pigment Epithelium; Topoisomerase I Inhibitors; Topotecan | 2016 |
Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy).
Topics: Carboplatin; Child; Child, Preschool; Electroretinography; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan | 2016 |
Secondary and tertiary intra-arterial chemotherapy for massive persistent or recurrent subretinal retinoblastoma seeds following previous chemotherapy exposure: long-term tumor control and globe salvage in 30 eyes.
Topics: Antineoplastic Agents; Carboplatin; Child, Preschool; Female; Humans; Infant; Male; Melphalan; Neoplasm Recurrence, Local; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan | 2016 |
Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Diarrhea; Disease-Free Survival; Eye Enucleation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infant; Male; Radiotherapy; Retinoblastoma; Salvage Therapy; Survival Rate; Topotecan; Vincristine; Vision Disorders; Visual Acuity | 2017 |
Diagnosis and management of secondary epipapillary retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Child, Preschool; Cryotherapy; Female; Humans; Hyperthermia, Induced; Infant; Infusions, Intra-Arterial; Male; Melphalan; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Tomography, Optical Coherence; Topotecan | 2017 |
Retinoblastoma Vitreous Seed Clouds (Class 3): A Comparison of Treatment with Ophthalmic Artery Chemosurgery with or without Intravitreous and Periocular Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Cohort Studies; Disease-Free Survival; Electroretinography; Female; Humans; Infusions, Intra-Arterial; Intravitreal Injections; Kaplan-Meier Estimate; Male; Melphalan; Neoplasm Seeding; Ophthalmic Artery; Retina; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan; Vitreous Body | 2017 |
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pelvic Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Argentina; Carboplatin; Child; Child, Preschool; Conservative Treatment; Disease-Free Survival; Feasibility Studies; Female; Humans; Infusions, Intra-Arterial; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan; Young Adult | 2018 |
Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Electroretinography; Female; Follow-Up Studies; Humans; Infant; Infusions, Intra-Arterial; Male; Melphalan; Ophthalmic Artery; Retina; Retinal Detachment; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome | 2018 |
Eye salvage in diffuse anterior retinoblastoma using systemic chemotherapy with periocular and intravitreal topotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Etoposide; Gonioscopy; Humans; Infant; Infusions, Intravenous; Intravitreal Injections; Male; Microscopy, Acoustic; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan; Vincristine | 2018 |
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Folic Acid; Humans; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Pipecolic Acids; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Ophthalmic Vascular Events after Primary Unilateral Intra-arterial Chemotherapy for Retinoblastoma in Early and Recent Eras.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Female; Fluorescein Angiography; Humans; Infant; Infusions, Intra-Arterial; Male; Melphalan; Ophthalmoscopy; Retinal Diseases; Retinal Neoplasms; Retinal Vessels; Retinoblastoma; Retrospective Studies; Risk Factors; Topotecan; Ultrasonography; Young Adult | 2018 |
Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child, Preschool; Humans; Infusions, Intra-Arterial; Injections, Spinal; Male; Melphalan; Retinal Neoplasms; Retinoblastoma; Topotecan | 2018 |
OPHTHALMIC VASCULAR EVENTS AFTER INTRA-ARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA: Real-World Comparison Between Primary and Secondary Treatments.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Choroid; Female; Fluorescein Angiography; Humans; Infant; Infant, Newborn; Infusions, Intra-Arterial; Male; Melphalan; Ophthalmic Artery; Retinal Diseases; Retinal Neoplasms; Retinal Vessels; Retinoblastoma; Retrospective Studies; Topotecan; Young Adult | 2019 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Republic of Korea; Topotecan | 2019 |
Association of electroretinography with visual outcomes after ophthalmic artery chemosurgery for retinoblastoma in ICRb D and E eyes.
Topics: Carboplatin; Case-Control Studies; Child; Child, Preschool; Electroretinography; Female; Humans; Infant; Infant, Newborn; Male; Melphalan; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan; Visual Acuity | 2019 |
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Drug Administration Schedule; Epirubicin; Female; Humans; Medication Adherence; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Topotecan; Tumor Burden; Young Adult | 2019 |
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult | 2019 |
Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Melphalan; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Topotecan; Transplantation, Autologous; Treatment Outcome | 2019 |
Management of retinoblastoma in older children (>5 years) using intra-arterial chemotherapy: Comparison of outcomes to prechemotherapy and intravenous chemotherapy eras.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Intravitreal Injections; Male; Melphalan; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Young Adult | 2019 |
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2020 |
Intra-arterial Chemotherapy as Primary Treatment for Cavitary Retinoblastoma: Excellent Response in Eight Tumors.
Topics: Antineoplastic Agents; Carboplatin; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Infant; Infusions, Intra-Arterial; Male; Melphalan; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Time Factors; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Ultrasonography | 2021 |
Carboplatin plus etoposide or topotecan for small-cell lung cancer.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
[New European approvals: Durvalumab - In first line metastatic small-cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Immunotherapy; Lung Neoplasms; Nivolumab; Small Cell Lung Carcinoma; Topotecan | 2020 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan | 2020 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan | 2020 |
Orbital Retinoblastoma Treated with Intra-arterial Chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Child, Preschool; Drug Therapy, Combination; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Male; Melphalan; Ophthalmic Artery; Orbital Neoplasms; Retinal Neoplasms; Retinoblastoma; Topoisomerase I Inhibitors; Topotecan | 2021 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Biochemical measures of ovarian function in female survivors of retinoblastoma treated with intra-arterial melphalan: an initial report.
Topics: Carboplatin; Child; Electroretinography; Female; Humans; Infant; Infusions, Intra-Arterial; Melphalan; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Survivors; Topotecan; Treatment Outcome | 2022 |
Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Chronic Disease; Cyclophosphamide; Etoposide; Humans; Polyketides; Recurrence; Retrospective Studies; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Topotecan | 2023 |